Regeneron Announces EYLEA Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee

Regeneron Pharmaceuticals, Inc. REGN today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration has voted unanimously to recommend that the FDA approve EYLEA™, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration at a dose of 2 milligrams (mg) every eight weeks, following three initial doses given every four weeks.